Physician profile
Hans M Sander
NPI 1285635813
$33,525.47
in general payments reported to CMS, 2019-2025
41 companies · $5,842 in 2025
The $5,842 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,588 · 2020: $1,925 · 2021: $3,176 · 2022: $5,909 · 2023: $6,980 · 2024: $6,107 · 2025: $5,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $1,000 · Education: $441 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,279.69 |
| Consulting Fee | $1,000.00 |
| Education | $440.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $208.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,396.64 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $6,432.12 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Genzyme Corporation | $2,522.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,866.76 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $1,786.21 | 2023-2025 | Zoryve |
| Ucb, INC. | $1,762.08 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,469.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,366.81 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,122.31 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $1,108.89 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Amgen INC. | $863.19 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $703.78 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $624.30 | 2022-2024 | Vtama |
| Leo Pharma INC. | $488.53 | 2019-2025 | Adbry |
| Mayne Pharma Commercial LLC | $455.65 | 2019-2025 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Sander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.